An Exploratory Study on the Treatment of Advanced Solid Tumors by Fast CAR T Cells
Trial Parameters
Brief Summary
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of fast autologous mesothelin (MSLN)-targeted chimeric antigen receptor (MSLN-CAR) T cells secreting PD-1 nanobodies in patients with solid tumors.
Eligibility Criteria
Inclusion Criteria: * Patients diagnosed with advanced solid tumors through histopathological diagnosis have a positive rate of ≥ 50% for mesothelin expression membrane in tumor tissue samples, PD-L1 positive expression, and sample sources within 2 years； * Late stage malignant solid tumor patients who have failed standard treatment or are intolerant to such treatment and do not have a standard effective treatment plan； * Greater than or equal to 18 years of age and less than or equal to 70 years of age on day of signing informed consent； * Life expectancy \>3 months； * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1； * Satisfactory organ and bone marrow function as defined by the following: 1. absolute neutrophil count must be greater than ≥ 1.5×109/L, lymphocyte count must be greater than ≥ 0.5×109/L, platelets must be greater than ≥ 90×109/L, hemoglobin must be greater than ≥ 90g/L without transfusion within 7 days or dependency on EPO; 2. Total bilirubin must